LL-37: A Human Cathelicidin Antimicrobial Peptide for Immune and Skin Research

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health facilitates access to LL-37 through licensed healthcare providers and compounding pharmacy partners. LL-37 is not FDA-approved for any indication. It is available by prescription only through licensed providers. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

The human body runs continuous antimicrobial surveillance. At every surface in contact with the external world, cells produce molecular weapons that kill bacteria on contact, recruit immune cells, and signal tissue repair. Most people have never heard of the peptide responsible for coordinating much of this in human skin, lungs, and gut. That is not because it is obscure. It is because it is so fundamental it rarely gets discussed outside of immunology research.

LL-37 is the only cathelicidin the human genome encodes. Here is what that means, what the published research supports, and which biomarkers connect to its activity.

Key Takeaways

• Regulatory Status: Not FDA-approved for any indication. As of April 2026, available only as a compounded prescription through licensed providers and licensed 503A compounding pharmacies.
• Research Stage: Studied in wound healing, skin immunology, antimicrobial defense, and innate immunity research; early-phase human clinical trials for topical wound applications have been completed.
• Availability: Not available through Superpower. LL-37 is on the FDA's 503A Category 1 bulk drug substances list; access, where available, is through licensed 503A compounding pharmacies under a patient-specific prescription. Not available over the counter in any formulation.
• Prescribing information: LL-37 on PubChem (CID 16198951)
• How it works: Disrupts microbial membranes directly and activates immune cell recruitment via formyl peptide receptor signaling.
• What the research shows: Preclinical and early clinical research has investigated LL-37's potential role in wound healing, antimicrobial defense at mucosal surfaces, and skin barrier immunity. The most advanced human trial data exists for topical wound applications.

What Is LL-37?

LL-37 is a 37-amino-acid cationic antimicrobial peptide derived from the C-terminal end of hCAP-18, the precursor protein encoded by the human CAMP gene. Agerberth and colleagues first characterized it in 1995, published in the Proceedings of the National Academy of Sciences, identifying it as the first human cathelicidin: cysteine-free, expressed in bone marrow and testis, and active against both gram-positive and gram-negative bacteria. Gudmundsson and colleagues followed in 1996, published in the European Journal of Biochemistry, characterizing the FALL39 gene and the biochemical processing pathway that converts the cathelin precursor protein hCAP-18 into mature LL-37 in granulocytes.

Mammals have many cathelicidins. Humans have exactly one. Zanetti's 2004 review, published in the Journal of Leukocyte Biology, describes cathelicidins as multifunctional peptides integrating antimicrobial killing, chemotaxis, wound healing, and apoptosis induction into a single molecular class. The 2006 review by Dürr, Sudheendra, and Ramamoorthy in Biochimica et Biophysica Acta, titled "LL-37, the only human member of the cathelicidin family of antimicrobial peptides," remains the canonical structure-function reference, covering LL-37's alpha-helical conformation, amphipathic structure, and the biophysical basis for its membrane-disrupting activity.

In the body, LL-37 is stored in neutrophil granules and secreted by keratinocytes, epithelial cells of the respiratory tract, and cells of the gastrointestinal mucosa. It is released in inactive form as the hCAP-18 precursor and cleaved to the active peptide by extracellular proteases. Sørensen and colleagues demonstrated in 2001, published in Blood, that proteinase 3 is the primary extracellular protease responsible for this cleavage upon neutrophil degranulation. Frohm and colleagues established in 1997, published in the Journal of Biological Chemistry, that LL-37 expression is induced in keratinocytes during inflammatory skin disorders, positioning it as part of the body's barrier-defense response rather than baseline homeostatic activity.

How LL-37 Works in the Body

Direct antimicrobial membrane disruption

LL-37 kills microorganisms through physical disruption of their lipid membranes. Its positive charge attracts it to negatively charged bacterial membranes, and its amphipathic alpha-helical structure inserts into and destabilizes the lipid bilayer. This mechanism is active against a broad spectrum of targets, including gram-positive and gram-negative bacteria, fungi, and enveloped viruses, and it retains activity against established biofilms — a 2023 review in World Journal of Microbiology and Biotechnology by Memariani and Memariani documenting LL-37 antibiofilm activity across at least 12 bacterial species, with cited primary studies reporting greater than 3-log10 reductions in Pseudomonas aeruginosa biofilm viability within 5 minutes of exposure at minimum inhibitory concentrations of 8–32 µg/mL. Because the mechanism is physicochemical rather than receptor-specific, resistance development is slower and less predictable than with antibiotics that target single molecular receptors. Braff and colleagues demonstrated in 2005, published in the Journal of Immunology, that proteolytic processing of cathelicidin peptides can dissociate antimicrobial killing activity from host immunostimulatory activity, indicating that these two functions operate through distinct structural requirements.

Immune cell chemotaxis via FPRL1

Beyond direct killing, LL-37 functions as a signaling molecule that recruits immune cells to sites of infection. De Yang and colleagues published a landmark study in 2000 in the Journal of Experimental Medicine demonstrating that LL-37 uses the formyl peptide receptor-like 1 (FPRL1) to chemoattract neutrophils, monocytes, and T cells. This finding established the mechanistic bridge between LL-37's innate antimicrobial role and its capacity to shape adaptive immune responses. FPRL1 is a G protein-coupled receptor expressed on multiple immune cell types. By activating it, LL-37 turns a local antimicrobial response into a coordinated immune mobilization event. This dual function, killing pathogens while simultaneously calling in immune reinforcements, defines LL-37's central role in the innate immune system.

Wound healing and angiogenesis

LL-37 participates in tissue repair beyond its antimicrobial role. Heilborn and colleagues published in the Journal of Investigative Dermatology in 2003 the foundational wound-healing study, showing in an ex vivo organ-cultured human skin model that antibody-mediated LL-37 neutralization inhibited re-epithelialization in a concentration-dependent manner and abolished Ki67 proliferation-marker immunoreactivity in wound epithelium, while chronic ulcer epithelium showed markedly deficient hCAP-18 expression compared with acute wound tissue (where hCAP-18 levels peak within 48 hours of injury). This deficiency in chronic wounds provides one rationale for investigating exogenous LL-37 in hard-to-heal wound contexts. Carretero and colleagues extended this in 2008, published in the Journal of Investigative Dermatology, with in vitro evidence in human HaCaT keratinocytes and in vivo evidence in ob/ob diabetic mice that adenoviral LL-37 delivery significantly improved re-epithelialization and granulation tissue formation, mediated through MAPK and PI3K-Akt signaling, Snail/Slug transcription factor activation, and matrix metalloproteinase upregulation. Koczulla and colleagues identified an additional dimension in 2003, published in the Journal of Clinical Investigation, demonstrating that LL-37/hCAP-18 induces angiogenesis through FPRL1 on endothelial cells: a 5 µg/pellet dose significantly increased erythrocyte-filled vessel formation in the chick chorioallantoic membrane assay (P<0.05), increased collateral vessel growth in a rabbit hindlimb ischemia model (P<0.05), and CRAMP-deficient mice showed significantly reduced wound revascularization (P<0.05) — establishing a vascular-support role during tissue repair.

Vitamin D regulation of LL-37 expression

LL-37 production is not constant. It is regulated by environmental and nutritional signals, and vitamin D is the most clinically significant of these. Liu and colleagues published a landmark 2006 study in Science demonstrating that Toll-like receptor 2/1 activation by Mycobacterium tuberculosis triggers upregulation of the vitamin D receptor and the enzyme CYP27B1 in human macrophages, which converts 25-hydroxyvitamin D to its active form (1,25-dihydroxyvitamin D). The active form then drives transcription of the CAMP gene, increasing LL-37 production and enhancing intracellular killing of the pathogen. The same paper found that individuals with low serum 25-hydroxyvitamin D showed reduced capacity to induce cathelicidin expression. This pathway means that vitamin D status is directly upstream of LL-37 availability in immune defense, and low vitamin D may functionally limit LL-37 production at sites of infection. For Superpower's audience, this creates a clinically actionable connection: knowing your vitamin D level is part of understanding your innate immune capacity.

What the Research Shows

Wound healing: topical clinical trials

The most advanced human trial data for LL-37 comes from topical wound-healing applications. A 2021 multicenter phase IIb double-blind, randomized, placebo-controlled trial in Wound Repair and Regeneration by Mahlapuu and colleagues evaluated topical LL-37 for hard-to-heal venous leg ulcers in 148 participants recruited across Poland and Sweden (mean age 67.6 years, median ulcer duration 20.3 months, mean wound size 11.6 cm²) using twice-weekly local applications at 0.5 mg/mL or 1.6 mg/mL versus placebo over a 13-week randomized double-blind treatment phase following a 3-week placebo run-in. The trial did not detect any significant difference in healing across the full cohort, but a pre-specified post-hoc analysis of the subgroup with large target wounds of at least 10 cm² (n=66) found that the 0.5 mg/mL dose achieved 28.1% complete wound closure versus 8.1% on placebo (P=0.0458; odds ratio 4.45), 61.9% versus 33.3% achieved ≥50% ulcer-area reduction (P=0.0294), and 47.2% versus 16.2% achieved ≥70% reduction (P=0.0149); the study drug was well-tolerated at both dose strengths with no serious safety concerns. A 2023 randomized, double-blind, placebo-controlled trial in Archives of Dermatological Research by Miranda and colleagues evaluated topical LL-37 cream versus placebo in patients with mild-infection diabetic foot ulcers, applied twice weekly for 4 weeks, and reported significantly greater granulation index in the LL-37 group at day 7 (p = 0.031), day 14 (p = 0.009), day 21 (p = 0.006), and day 28 (p = 0.037); inflammatory cytokines IL-1α and TNF-α rose similarly in both groups (p > 0.05) and aerobic bacterial colonization did not differ significantly between groups, suggesting the wound-healing benefit was not explained by either a reduction in local inflammatory signaling or antimicrobial clearance. The small single-center cohort and the unresolved mechanism limit the strength of these findings. Together, these trials represent the best available human clinical evidence for LL-37 in wound healing: promising signals, particularly in difficult wound types, but without the phase III evidence base that would establish efficacy across broad populations. Results from these trials used the topical formulation; injectable LL-37 has a different safety and pharmacokinetic profile and has not completed similar clinical evaluation.

Antimicrobial activity at mucosal surfaces

Chromek and colleagues published in Nature Medicine in 2006 demonstrating that cathelicidin protects the urinary tract from invasive bacterial infection in vivo, using CRAMP-deficient mice and neutrophil-depleted mice, which exhibited greater susceptibility to ascending E. coli infection than wild-type controls, and showing that clinical E. coli strains more resistant to LL-37 caused more severe urinary tract infections than LL-37-susceptible strains. This in vivo evidence supports the general principle that endogenous LL-37 production matters for protection at mucosal surfaces, even though these findings derive from animal models and cannot be directly extrapolated to exogenous LL-37 administration in humans.

Antiviral activity

Barlow and colleagues published in PLoS ONE in 2011 demonstrating that nebulized LL-37 has direct antiviral activity against influenza A in murine infection: at 500 µg/mL administered daily, LL-37 reduced day-3 lung viral titers by approximately 70–80% (P≤0.05), comparable to nebulized zanamivir at the same concentration, significantly improved survival versus saline control (P≤0.001), and significantly lowered IL-1β and GM-CSF in bronchoalveolar lavage fluid (P≤0.05). Harcourt and colleagues extended the antiviral profile in 2016, published in BMC Research Notes, with evidence that LL-37 inhibits respiratory syncytial virus (RSV) infection in polarized human airway epithelial Calu-3 cells: 50 µg/mL LL-37 applied prophylactically (1-hour co-incubation before infection) significantly reduced RSV-M viral-genome detection at 7 days post-infection (P≤0.05) and significantly reduced associated chemokine expression (P≤0.05), while therapeutic post-infection treatment had minimal effect. These findings are in vitro and animal data; no completed human clinical trials have evaluated exogenous LL-37 for antiviral respiratory indications as of April 2026.

Dual-Edged Biology: Where LL-37 Becomes a Disease Driver

LL-37's biology is not uniformly beneficial. In several inflammatory and autoimmune contexts, elevated or abnormally processed LL-37 is a pathological driver rather than a protective one. Understanding these dual roles is essential for any serious discussion of LL-37 in a clinical context.

Rosacea: LL-37 as an inflammatory mediator

Yamasaki and colleagues published a landmark paper in Nature Medicine in 2007 demonstrating that increased serine protease (kallikrein 5) activity and abnormal cathelicidin processing drive rosacea skin inflammation. In rosacea-affected skin, cathelicidin peptides are present in greater quantities and in different proteolytic forms compared to normal skin. These abnormal forms are more inflammatory than standard LL-37. In this context, LL-37 is a disease mediator. Exogenous LL-37 supplementation in someone with rosacea or rosacea-prone skin could theoretically worsen the condition. Providers evaluating LL-37 for skin applications should assess for rosacea as part of the candidacy evaluation.

Psoriasis: LL-37 as an autoantigen

Lande and colleagues published a landmark paper in Nature in 2007 demonstrating that LL-37 complexes with self-DNA to activate plasmacytoid dendritic cells via TLR9, driving the interferon-alpha response that initiates psoriasis. LL-37 acts as a molecular bridge that converts normally immunologically inert self-DNA into a potent trigger for immune activation, breaking immune tolerance. This establishes LL-37 as a validated psoriasis autoantigen. In individuals with psoriasis or a predisposition to autoimmune skin disease, the safety profile of exogenous LL-37 carries additional uncertainty. This is a meaningful cautionary note that should inform any prescribing decision.

Cancer: tissue-dependent roles

Wu and colleagues published a review in the International Journal of Cancer in 2010 summarizing primary literature on LL-37's tissue-dependent dual roles in human cancer — overexpression has been associated with breast, ovarian, and lung tumor development or progression in published primary studies, while LL-37 has been reported to suppress tumorigenesis in gastric and colon cancer contexts, with the divergent effects attributed to differences in surface receptor activation across cancer cell lineages. Piktel and colleagues updated this analysis in 2016, published in Archives of Immunology and Therapeutic Experimentation, with a mechanistic breakdown by tumor type confirming that these divergent effects depend on which surface receptors are activated in different cancer cell lineages. The angiogenic activity of LL-37 documented by Koczulla and colleagues is likely a contributing mechanism for its pro-tumor effects in cancers where neovascularization promotes growth. Individuals with active or prior malignancy are not appropriate candidates for LL-37 without thorough provider evaluation of the specific cancer type and context.

LL-37 vs. Other Cathelicidins and Defensins

LL-37 belongs to the broader cathelicidin family of antimicrobial peptides, but it is the only cathelicidin encoded in the human genome. Other mammals have multiple cathelicidins: bovine BMAP-28, porcine protegrins, and murine CRAMP (the rodent homolog of LL-37). These species-specific cathelicidins share structural and functional similarities with LL-37 but are not the same molecule and are not produced by humans. Dürr and colleagues' 2006 review explains the structural uniqueness of LL-37 within this family in detail.

Defensins are a separate class of antimicrobial peptides also present in humans. They differ from cathelicidins structurally (defensins contain disulfide-bonded cysteine residues, while LL-37 is cysteine-free) and functionally (defensins are primarily pore-forming rather than membrane-disrupting through amphipathic insertion). The human genome encodes both alpha-defensins (expressed primarily in neutrophils and Paneth cells) and beta-defensins (expressed in epithelial cells). LL-37 and defensins are complementary components of the same innate immune system rather than competing molecules. Some research suggests they have additive effects when present together at sites of infection, but no human clinical data establishes a therapeutic role for combining exogenous cathelicidin with exogenous defensins.

Side Effects and Safety Considerations

The safety profile of exogenous LL-37 administration is informed by a small number of human trials, primarily using topical formulations, and by extrapolation from the compound's known biology.

Reported in topical clinical studies:

• Local skin reactions at the application site (erythema, irritation), consistent with the expected inflammatory activity of a cationic antimicrobial peptide on disrupted skin
• No serious systemic adverse events reported in the Mahlapuu 2021 or Miranda 2023 trials at the doses studied

Theoretical risks based on mechanism:

• Concentration-dependent cytotoxicity: LL-37 can disrupt mammalian cell membranes at higher concentrations, as its amphipathic structure is not fully selective for microbial versus mammalian membranes. Oren and colleagues established the structural basis for this non-cell-selective activity in a 1999 Biochemical Journal paper, showing that the same amphipathic helix that lyses bacteria will also permeabilize mammalian lipid bilayers above a threshold concentration. This is a recognized property of cationic antimicrobial peptides and sets a ceiling on the concentrations that can be administered safely
• Autoimmune activation risk in individuals with psoriasis, lupus, or other conditions where LL-37 is a known autoantigen or disease mediator
• Worsening of rosacea in individuals with cathelicidin-mediated skin inflammation
• Theoretical pro-tumor activity in individuals with active breast, ovarian, or lung malignancy based on the dual-edged cancer biology described above

Systemic safety data: Long-term human safety data for injectable LL-37 is not available as of April 2026. The clinical trial evidence described in this article used topical formulations. Injectable administration represents a meaningfully different pharmacokinetic exposure. Any use of injectable LL-37 represents a limited-evidence-base clinical decision by the prescribing provider.

Who Is LL-37 Typically Prescribed For?

Individuals with chronic or hard-to-heal wounds

The existing human trial evidence is concentrated in topical wound-healing applications, specifically venous leg ulcers and diabetic foot ulcers. These are populations where LL-37 deficiency in wound epithelium is well-documented and where standard-of-care approaches frequently fail to achieve closure. Providers considering LL-37 in wound care contexts should review the published trial results with attention to study populations, formulation type, and the nuanced findings, including the subgroup analyses from Mahlapuu 2021, before making prescribing decisions.

Individuals interested in the vitamin D and immune function relationship

LL-37's connection to vitamin D makes it relevant to individuals whose interest in immune optimization begins with foundational biomarker assessment. Because vitamin D status directly regulates LL-37 expression at the gene level, quantifying vitamin D is a clinically meaningful starting point before any conversation about LL-37 supplementation. Providers may evaluate LL-37 in individuals with documented vitamin D deficiency combined with recurrent infections or impaired wound healing, though this use case has not been studied in controlled trials.

Who Should Not Use LL-37

A licensed provider will evaluate individual risk factors before prescribing. The following represent conditions requiring additional clinical scrutiny or where use is generally not appropriate:

• Active or personal history of psoriasis: LL-37 is a validated psoriasis autoantigen; exogenous administration may trigger or worsen disease via TLR9-mediated plasmacytoid dendritic cell activation
• Rosacea or rosacea-prone skin: abnormal cathelicidin processing is central to rosacea pathophysiology; additional exogenous LL-37 may exacerbate inflammation
• Active malignancy, particularly breast, ovarian, or lung cancer, where LL-37 has documented pro-tumorigenic activity in published research
• Individuals with systemic autoimmune conditions involving innate immune dysregulation, where additional immune activation carries uncertain and potentially elevated risk
• Pregnancy: safety has not been established in pregnancy; systemic or injectable use is not appropriate without clear clinical indication and provider judgment
• Known hypersensitivity to LL-37 or any compounded formulation excipients

A licensed provider will conduct a full clinical evaluation before determining eligibility. This list is not exhaustive.

Biomarkers to Monitor With LL-37

Establishing a baseline before beginning any compounded compound, and tracking relevant markers during use, converts a clinical decision from a guess into an informed assessment. For LL-37, the most clinically relevant biomarkers connect to its known upstream regulators, its inflammatory activity, and the immune pathways it activates.

• 25-Hydroxyvitamin D: The most directly relevant upstream biomarker for LL-37. Because the vitamin D receptor drives CAMP gene transcription, serum vitamin D status is a functional proxy for the body's capacity to produce LL-37 in response to infection. Low vitamin D is associated with lower cathelicidin induction as established in Liu et al. 2006. Baseline testing informs whether vitamin D optimization should precede any discussion of exogenous LL-37 supplementation. Reference ranges vary by lab and individual; your provider will interpret your specific result in context.
• High-sensitivity C-reactive protein (hs-CRP): A broad marker of systemic inflammation. LL-37 both responds to and drives inflammatory signaling. Baseline hs-CRP establishes the inflammatory context before use and provides a reference point for tracking whether inflammatory activity changes during therapy. In wound-healing applications, a decrease may suggest improved local resolution; unexpected increases warrant re-evaluation. Reference ranges vary by lab and individual.
• White blood cells (WBC) with differential: LL-37 chemoattracts neutrophils, monocytes, and T cells via FPRL1 signaling. Baseline WBC and differential quantify the immune cell compartment available to respond. Changes in neutrophil or monocyte counts during therapy may reflect systemic immune activation or, at high doses, could indicate unintended systemic effects. Your provider will determine which monitoring intervals are appropriate based on formulation and clinical presentation.

Is LL-37 Legal?

As of April 2026, LL-37 is not FDA-approved for any therapeutic indication. There is no FDA-reviewed NDA, BLA, or approved clinical indication for LL-37. It is not available over the counter in any formulation.

LL-37 is on the FDA's Category 1 bulk drug substances list under Section 503A of the Federal Food, Drug, and Cosmetic Act. This classification means it may be legally compounded with a patient-specific prescription from a licensed prescriber and dispensed by a licensed 503A compounding pharmacy. LL-37 is not available through Superpower. All prescribing represents the independent clinical judgment of the provider.

Compound reference data: PubChem CID 16198951.

What to Test Before Starting LL-37

Establishing a baseline before beginning LL-37 is clinically important for the same reason it is important before beginning any immunomodulatory compound. The markers below directly connect to LL-37's mechanism of action, its upstream regulation, and the conditions that represent contraindications or elevated risk.

• 25-Hydroxyvitamin D: Directly upstream of CAMP gene transcription. Establishes whether endogenous LL-37 production may already be suppressed due to vitamin D deficiency, and whether vitamin D optimization should precede or accompany any LL-37 prescription.
• hs-CRP: Establishes systemic inflammatory baseline. Relevant both as a monitoring marker during wound-healing applications and as a screen for pre-existing systemic inflammation that may affect the immune response to LL-37.
• WBC with differential: Establishes immune cell compartment status. Neutropenia or lymphopenia at baseline changes the clinical context for a compound that depends on intact immune cell populations for part of its proposed mechanism.
• Skin condition and autoimmune history assessment: Not a biomarker, but a critical pre-prescribing evaluation. Psoriasis, rosacea, lupus, and other autoimmune conditions involving LL-37 biology are direct contraindications or require additional scrutiny.
• Comprehensive metabolic panel: Assesses liver and kidney function. Relevant as a general safety baseline before starting any compounded prescription compound.

What Your Biomarkers May Show During LL-37 Use

When LL-37 is being used in a wound-healing context and functioning as the research suggests, the expected direction of change is: wound granulation and re-epithelialization progress, local inflammation resolves, and systemic inflammatory markers (hs-CRP) return toward baseline as the wound closes. WBC differential values should remain within normal ranges in the absence of concurrent systemic infection.

Unexpected findings that warrant provider evaluation include: rising hs-CRP without evidence of active wound infection, skin reactions in areas beyond the application site, and any signs consistent with autoimmune activation in individuals with relevant history. Because the clinical evidence base for injectable LL-37 is limited, unexpected changes in any tracked biomarker should prompt clinical review rather than dose continuation.

The principle of measuring first, then tracking how values respond, is central to Superpower's approach to preventive health. Every decision about compounded immune-active peptides should begin with knowing where your biomarkers stand. Data gathered before starting makes changes during therapy interpretable. Data gathered only afterward cannot establish a baseline comparison.

If you are exploring LL-37 as part of a broader immune and skin health evaluation, a consultation with a licensed provider is the appropriate next step. Any provider you work with should review your biomarker baseline, evaluate candidacy, and determine whether LL-37 is clinically appropriate for your specific situation.

IMPORTANT SAFETY INFORMATION

LL-37 is NOT FDA-approved for any indication. As of April 2026, LL-37 is available only through licensed compounding pharmacies by prescription under Section 503A of the Federal Food, Drug, and Cosmetic Act. It is on the FDA's Category 1 bulk drug substances list. All prescribing represents the independent clinical judgment of the provider. Superpower Health does not prescribe, sell, compound, or facilitate access to LL-37; this page is provided for educational and informational purposes only.

Dual-edged biology: LL-37 is a validated psoriasis autoantigen and is an inflammatory mediator in rosacea. It also has documented pro-tumorigenic activity in breast, ovarian, and lung cancers. These are not theoretical risks; they are established findings in peer-reviewed literature and must be evaluated by the prescribing provider before use.

Contraindications and elevated-risk populations: psoriasis or personal history of psoriasis; rosacea or rosacea-prone skin; active or history of breast, ovarian, or lung cancer; systemic autoimmune conditions involving innate immune dysregulation; pregnancy; known hypersensitivity to LL-37 or formulation excipients.

Common side effects (topical clinical trials): local skin reactions at application site (erythema, irritation). Concentration-dependent cytotoxicity is a theoretical risk at elevated systemic concentrations. Long-term safety data for injectable LL-37 in humans is not available as of April 2026.

Systemic and injectable use: the clinical trial evidence for LL-37 used topical formulations. Injectable administration represents a different pharmacokinetic profile with a more limited human safety data set. Not a complete list of risks. For compound reference data, see PubChem CID 16198951.

This content is provided by Superpower Health for educational and informational purposes only. LL-37 is not FDA-approved for any indication and is not available through Superpower. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

Additional Questions

What biomarkers should I get before starting LL-37?

The core pre-treatment markers are 25-hydroxyvitamin D, hs-CRP, and WBC with differential. These establish your vitamin D status (which regulates LL-37 gene expression), your baseline inflammatory tone, and the status of the immune cell populations LL-37 recruits. A comprehensive metabolic panel rounds out the safety baseline. Your provider will determine whether additional markers are appropriate based on your clinical presentation and the intended formulation.

Is LL-37 appropriate for wound healing?

Human clinical evidence for topical LL-37 in wound healing is limited but exists. The Mahlapuu 2021 multicenter phase IIb RCT evaluated topical LL-37 in 148 patients with hard-to-heal venous leg ulcers and found no significant benefit across the full cohort, with a potential signal in larger ulcers on post-hoc analysis. The Miranda 2023 randomized trial in diabetic foot ulcers reported consistently greater granulation in the LL-37 group. Topical wound-healing use is the application with the most human trial data, but evidence does not yet meet the threshold for an established indication. A provider will determine whether the available evidence supports use in your specific wound context.